来伐替尼治疗后雷莫昔单抗治疗无法切除的肝细胞癌的进展

StephenW

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma
Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Chikara Ogawa, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa ... Show more
Gastroenterology Report, goaa042, https://doi.org/10.1093/gastro/goaa042
Published:
10 October 2020
Article history

    pdfPDF
    Split View
    Cite
    Permissions Icon Permissions
    Share

Abstract
Background

Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment.
Methods

Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner.
Results

The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score was −2.19. Of the 28 patients, 23 were male, 21 were classified as Child–Pugh A and 7 as Child–Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1/26) and the disease-control rate was 42.3% (11/26), with a median period to progression of 2.0 months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2.
Conclusions

The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.

StephenW

来伐替尼治疗后雷莫昔单抗治疗无法切除的肝细胞癌的进展后治疗
平冈淳史，熊田隆史，多田俊史，小川知kara，谷谷次二，福西伸弥，A川正德，广冈昌史，Tsu邦邦彦，石川彻...
胃肠病学报告，goaa042，https://doi.org/10.1093/gastro/goaa042
发布时间：
2020年10月10日
文章历史

    PDF格式
    拆分视图
    引用
    权限图标权限
    分享

抽象
背景

Lenvatinib在日本被用于不可切除的肝细胞癌（u-HCC）一线以及二线和三线治疗。 lenvatinib治疗后进行治疗后，我们评估了新开发的ramucirumab的治疗效果。
方法

在2018年5月至2020年1月期间，在日本16个不同机构的385例u-HCC患者中接受了lenvatinib治疗，其中28例接受了拉莫昔单抗作为下一种治疗方法，并回顾性评估了治疗反应。
结果

接受雷莫昔单抗治疗的28例患者的中位年龄为70岁，白蛋白-胆红素得分的中位值为-2.19。在这28例患者中，有23例为男性，有21例归类为Child-Pugh A，7例归类为Child-Pugh B，其中25例为巴塞罗那临床肝癌C期。在14例，3例， 9例行，5例行第四行。仅26例获得了治疗反应。客观缓解率为3.8％（1/26），疾病控制率为42.3％（11/26），进展中位时间为2.0个月。雷莫昔单抗停药的原因是16例疾病进展和2例3级不良事件（胃肠道出血，腹水）。
结论

在我们的早期经验中未见雷莫昔单抗对Lenvatinib进行后治疗的预期疗效。

StephenW

https://academic.oup.com/gastro/ ... tro/goaa042/5920587